Qianmo Biotechnology

Qianmo Biotechnology is an innovative biotech company focused on high-throughput single-cell functional screening and therapeutic antibody discovery. Headquartered in Hangzhou, China, the company utilizes proprietary microfluidic and single-cell sequencing technologies to accelerate the identification of potent antibody candidates. Their platform enables the direct screening of primary B cells based on functional output rather than just binding affinity, which enhances the quality and success rate of lead molecules. Qianmo targets a variety of therapeutic areas, including oncology and immunology, through both internal R&D and strategic partnerships with pharmaceutical companies. The company aims to streamline the hit-to-lead process and provide more efficient drug discovery solutions for complex diseases.